Investing.com -- Regeneron (NASDAQ: REGN ) Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell 1.5% following a U.S. appeals court decision that upheld a previous ruling, effectively denying a stay on sales of biosimilar versions of its drug Eylea. The court found Regeneron’s remaining arguments in the patent case to be "unpersuasive."

The decline came after the court affirmed its earlier decision, which had denied Regeneron’s motion for infringement on the grounds that the company did not demonstrate a likelihood of success in proving that Amgen Inc (NASDAQ: AMGN ). had infringed on U.S. Patent 11,084,865, claimed to cover a vial containing Eylea. As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%.

This legal setback for Regeneron comes amid competitive pressures in the biologics market, where biosimilars are increasingly offering alternatives to established products like Eylea. The decision may potentially pave the way for Amgen and other competitors to capture market share with their biosimilar products.

Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents a notable development for both Regeneron and the broader pharmaceutical industry.

Regeneron’s stock movement today reflects the immediate market response to the legal proceedings, highlighting the importance of patent protection and litigation outcomes in the biotech and pharmaceutical sectors. As the situation evolves, market participants will continue to monitor the implications of this decision for Regeneron’s financial performance and competitive position in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.